US-based medical device firm Tendyne Holdings has started patient enrolment in its multi-centre global feasibility trial of its Tendyne Bioprosthetic Mitral Valve (TMVR) system in patients with symptomatic mitral regurgitation of degenerative or functional etiology.

As part of the trial, the Tendyne Bioprosthetic Mitral Valve was successfully implanted in the first patient in the US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial is designed to provide early insights into the safety and performance of the Tendyne Bioprosthetic Mitral Valve system in these patients.

The implantation was conducted by principal investigator Dr Wesley Pederson and co-principal investigator Dr Saeid Farivar.

"The TMVR system is designed to offer physicians total control during the procedure with a device that is fully repositionable and retrievable."

Dr Pederson said: "We are proud to be the first centre in the US to implant the Tendyne Bioprosthetic Mitral Valve.

See Also:

"The implant was simple and straightforward and the patient is doing well. This milestone marks the beginning of a new era of transcatheter valve replacement for patients with malfunctioning mitral valves."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The TMVR system is designed to offer physicians total control during the procedure with a device that is fully repositionable and retrievable.

The device comprises of a trileaflet porcine pericardial valve sewn onto a nitinol frame that is tethered to the apex of the heart.

Dr Farivar said: "The Tendyne Bioprosthetic Mitral Valve was implanted in a beating heart, without open heart surgery, without cardiopulmonary bypass, and the device performed as intended with a remarkable absence of post procedural mitral regurgitation.

"We believe this device has the potential to offer a safe and effective solution for patients that are not suitable candidates for traditional open heart mitral valve surgery."